Piper Jaffray analyst William Quirk recommends using today's post-earnings weakness in shares of Hologic as a buying opportunity. He lowered his price target for the stock to $48 from $49 and reiterates an Overweight rating on the name. Hologic lowered its guidance by $40M due largely to CynoSure, Quirk tells investors in a research note. With CynoSure approaching just 10% of the overall business and "seemingly stabilized," longer-term investors can increase Hologic positions for the accelerated organic growth from new product sales, Quirk contends.